OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.
OncoSil Medical Ltd reported record quarterly dose sales for Q3 FY25, driven by increased clinical adoption of the OncoSil™ device. The company saw a 233% increase in dose sales compared to the previous year, contributing to an 83% rise in year-to-date sales and a 135% increase in year-to-date revenues. This growth highlights the company’s successful market penetration and strategic advancements, including receiving MDR approval and expanding its presence in German hospitals. The financial results indicate a promising outlook for future revenue growth as sales figures are expected to be more fully realized in upcoming quarters.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company focuses on the development and clinical adoption of the OncoSil™ device, targeting key geographic markets to enhance its market presence.
Technical Sentiment Signal: Buy
Current Market Cap: A$18.43M
See more data about OSL stock on TipRanks’ Stock Analysis page.